NCT01463215View on ClinicalTrials.gov

Clinical Trial of Ambroxol in Patients With Type I Gaucher Disease

PHASE1/PHASE2SuspendedINTERVENTIONAL

Enrollment

20

Participants

Timeline

Start Date

December 31, 2012

Primary Completion Date

December 31, 2014

Study Completion Date

August 31, 2015

Conditions

Type I Gaucher Disease

Interventions

DRUG

Ambroxol

Ambroxol at a dose level of 187.5 or 225 mg/day will be given once daily by mouth for 2 months.

Trial Locations (1)

08852

ExSAR Corporation, Monmouth Junction

Sponsors

Lead Sponsor

Exsar Corporation

All Listed Sponsors

lead

Exsar Corporation

INDUSTRY